1-1banner
 
medpundit
 

 
Commentary on medical news by a practicing physician.
 

 
Google
  • Epocrates MedSearch Drug Lookup




  • MASTER BLOGS





    "When many cures are offered for a disease, it means the disease is not curable" -Anton Chekhov




    ''Once you tell people there's a cure for something, the more likely they are to pressure doctors to prescribe it.''
    -Robert Ehrlich, drug advertising executive.




    "Opinions are like sphincters, everyone has one." - Chris Rangel



    email: medpundit-at-ameritech.net

    or if that doesn't work try:

    medpundit-at-en.com



    Medpundit RSS


    Quirky Museums and Fun Stuff


    Who is medpundit?


    Tech Central Station Columns



    Book Reviews:
    Read the Review

    Read the Review

    Read the Review

    More Reviews

    Second Hand Book Reviews

    Review


    Medical Blogs

    rangelMD

    DB's Medical Rants

    Family Medicine Notes

    Grunt Doc

    richard[WINTERS]

    code:theWebSocket

    Psychscape

    Code Blog: Tales of a Nurse

    Feet First

    Tales of Hoffman

    The Eyes Have It

    medmusings

    SOAP Notes

    Obels

    Cut-to -Cure

    Black Triangle

    CodeBlueBlog

    Medlogs

    Kevin, M.D

    The Lingual Nerve

    Galen's Log

    EchoJournal

    Shrinkette

    Doctor Mental

    Blogborygmi

    JournalClub

    Finestkind Clinic and Fish Market

    The Examining Room of Dr. Charles

    Chronicles of a Medical Mad House

    .PARALLEL UNIVERSES.

    SoundPractice

    Medgadget
    Health Facts and Fears

    Health Policy Blogs

    The Health Care Blog

    HealthLawProf Blog

    Facts & Fears

    Personal Favorites

    The Glittering Eye

    Day by Day

    BioEdge

    The Business Word Inc.

    Point of Law

    In the Pipeline

    Cronaca

    Tim Blair

    Jane Galt

    The Truth Laid Bear

    Jim Miller

    No Watermelons Allowed

    Winds of Change

    Science Blog

    A Chequer-Board of Night and Days

    Arts & Letters Daily

    Tech Central Station

    Blogcritics

    Overlawyered.com

    Quackwatch

    Junkscience

    The Skeptic's Dictionary



    Recommended Reading

    The Doctor Stories by William Carlos Williams


    Pox Americana: The Great Smallpox Epidemic of 1775-82 by Elizabeth Fenn


    Intoxicated by My Illness by Anatole Broyard


    Raising the Dead by Richard Selzer


    Autobiography of a Face by Lucy Grealy


    The Man Who Mistook His Wife for a Hat by Oliver Sacks


    The Sea and Poison by Shusaku Endo


    A Midwife's Tale by Laurel Thatcher Ulrich




    MEDICAL LINKS

    familydoctor.org

    American Academy of Pediatrics

    General Health Info

    Travel Advice from the CDC

    NIH Medical Library Info

     



    button

    Wednesday, February 01, 2006

    Flu Blues II: Sanofi-Pasteur has sold out of next year's flu vaccine already. From their vaccine ordering website:

    During the first 30 minutes of accepting prebooking requests, the company received over 40,000 phone calls and more than 200,000 calls came in during the first eight hours. As a result of the unprecedented demand, the company has committed all influenza vaccine doses planned for production for the next season except its no preservative Fluzone vaccine in pediatric doses. Sanofi pasteur anticipated a surge in demand for its influenza vaccine and doubled the capacity of its phone lines and on-line ordering systems. Under normal conditions, the company receives an average of 1,500 customer calls per day. During the eight-hour period from noon to 8 PM yesterday, the company received as many calls as it normally receives in a six-month period.

    The company plans to produce approximately 50 million doses of all Fluzone vaccine formulations for U.S. distribution by the end of October. Additional doses could be produced for delivery in November or December based on customer needs and production yields. To determine customer need, sanofi pasteur established a waiting list of customers who were unable to prebook and will contact those providers to offer the alternative of accepting later delivery. Customers willing to accept later delivery will have the option to cancel their request later in the year if they are able to obtain earlier delivery from another supplier. At this time, the company is no longer accepting additional customers on the waiting list.

    The company is currently unable to supply the entire U.S. influenza vaccine market. However, based on public statements made by other influenza vaccine manufacturers, the company anticipates that there will be an adequate supply of vaccine to meet the nation’s needs for the 2006-2007 season. Sanofi pasteur is sending apologies to its customers for the frustration they experienced in attempting to place their requests. Immunization providers who were unable to prebook their vaccine with sanofi pasteur will likely be able to look to other manufacturers to meet their vaccine needs.


    One of those other manufacturers would be Chiron, which had production problems for the past two years, and which this year, shipped their product to their big customers (chain stores, etc.) before they shipped it to their physician customers. (But whose distributors are still taking orders for next year's vaccine.) I know doctors who didn't recieve their order until the end of December. By that time, most of their patients had gotten the vaccine elsewhere. That left one group practice with a $20,000 loss. Would you want to order from that company again? Or even take a chance on purchasing the flu vaccine at all?

    One reason that Sanof-Pasteur had such a quick run is that they have been reliable about delivering the vaccine to all its customers regardless of size, and because they haven't had the history of production problems that Chiron has had.

    GlaxoSmithKline also has a flu vaccine, although it was approved under an accelerated FDA program, which leaves some physicians a little leary of it (including this one). Just how "accelerated" was the approval process and what steps got skipped?

    Accelerated approval allows products that treat serious or life-threatening illnesses to be approved based on successfully achieving an endpoint that is reasonably likely to predict ultimate clinical benefit, usually one that can be studied more rapidly than showing protection against disease. In this case, the manufacturer demonstrated that after vaccination with Fluarix adults made levels of protective antibodies in the blood that FDA believes are likely to be effective in preventing flu. GlaxoSmithKline, the manufacturer of Fluarix, will do further clinical studies as part of the accelerated approval process to verify the clinical benefit of the vaccine.

    A few too many "believe's" and "likely's" in their for my comfort.

    UPDATE: Here's more on the surge:

    A flurry of physicians attempting to order influenza vaccine for the 2006-07 flu season directly from manufacturer sanofi pasteur temporarily "maxed out" the Web servers supporting the company's VaccineShoppe.com site Jan. 31, according to John Zahradnik, M.D., sanofi pasteur's director of immunization policy.

    The ordering frenzy that followed sanofi pasteur's previously announced noon EST opening of physician prebooking for next season's flu vaccine also overloaded the company's toll-free ordering phone lines, despite the addition of extra staff to handle the anticipated greater volume.

    The result: Many would-be visitors to the Web site couldn't get through, especially early in the afternoon. Some switched to the phone lines and succeeded in their efforts to prebook vaccine; others still could not make those connections. Members of the Academy's Influenza Vaccine Task Force reported mixed results when they tried to order vaccine from sanofi pasteur that day. Those who eventually succeeded in prebooking vaccine using one or the other method typically did so only later that evening.


    The distribution system, obviously, continues to be imperfect:

    "It's an indication that this whole system of flu vaccine production, purchasing and distribution -- from egg to arm -- doesn't work. The entire ordering process needs to be examined, with preference given to those who serve high-risk patients -- physicians, hospitals and long-term care facilities.

    "This is just another example of the larger fact that this system isn't working. The manufacturers, distributors, CDC and organized medicine are going to have to work out a better system for getting influenza vaccine into the hands of physicians."


    I think we have to face it. We simply don't have the ability to make enough flu vaccine for everyone. Maybe we need to go back to just recommending it for those who are at true risk from influenza. And just missing a few days from work doesn't count as risk.
     

    posted by Sydney on 2/01/2006 10:14:00 PM 0 comments

    0 Comments:

    Post a Comment

    This page is powered by Blogger, the easy way to update your web site.

    Main Page

    Ads

    Home   |   Archives

    Copyright 2006